August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Ilyas Sahin: The Role of CLDN18.2-targeting ADC in Refractory Advanced GEJ Cancer Patients
Jul 18, 2025, 15:59

Ilyas Sahin: The Role of CLDN18.2-targeting ADC in Refractory Advanced GEJ Cancer Patients

Ilyas Sahin, Medical Oncologist at Massachusetts General Hospital, shared a post on X:

“Two phase 1 trials published in Nature Medicine (IBI343 and SHR-A1904) tested CLDN18.2-targeting ADCs in heavily pretreated, refractory advanced gastric/GEJ cancer patients with no standard options left. Both drugs showed ORR of 25–29% and PFS of ~5.5–5.8 months.

Ongoing phase 3 studies will further define their role in treatment…”

Title: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

Authors: Jia Liu, Jianwei Yang, Yuping Sun, Jifang Gong, Jinbo Yue, Yueyin Pan, Meili Sun, Rongfeng Song, Xiuying Xiao, Andrea Tazbirkova, Jian Ruan, Zhenyang Liu, Zimin Liu, Zhihua Li, Lili Sheng, Yanru Qin, Jieer Ying, Xianjun Yu, Jian Zhang, Yiping Mou, Chuangxin Lu, Ping Chen, Suyi Li, Jie Li, Xiujuan Qu, Ting Deng, Juan Du, Aiping Zhou, Enxiao Li, Xianglin Yuan, Xinjun Liang, Weiming Yu, Michelle Morris, Yang Luo, Xin Zhao, Yingmei Guo, Hui Zhou, Lin Shen

You can read the Full Article in the Nature Medicine.

Ilyas Sahin: The Role of CLDN18.2-targeting ADC in Refractory Advanced GEJ Cancer Patients

 

Title: The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial

Authors: Dan-Yun Ruan, Hao-Xiang Wu, Su-Xia Luo, Wen-Wen Huang, Xin-Jun Liang, Zuo-Xing Niu, Qi Dang, Hong-Li Li, Zhan-Yu Pan, Hong-Xia Lu, Yan-Qiao Zhang, Xing-Ya Li, Xiu-Ying Xiao, Shi-Rong Cai, Yu-Gang Dong, Jian Zhang, Zhou Li, Hai-Tao Lan, Xin Wang, Ying Zhou, Lian Liu, He-Li Liu, Ping-Sheng Xu, Ai-Li Suo, Rui-Nuo Jia, Yong-Qiang Li, Xiao-Dong Peng, Si-Chen Wang, Ai-Ai Yu, Jie Xie, Miao-Zhen Qiu, Rui-Hua Xu

You can read the Full Article in the Nature Medicine.

Ilyas Sahin: The Role of CLDN18.2-targeting ADC in Refractory Advanced GEJ Cancer Patients

 

More posts featuring Ilyas Sahin on OncoDaily.